ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI To Push “Cancer Prevention Awareness” This Month; Three RFPs Delayed For Changes

February 17, 1984

Manville Sues U.S. Over “Withheld” Wartime Data

July 22, 1983

House Members Urge FDA to Review Fast Track Policies

July 5, 2002

NCI CTEP-Approved Trials For the Month of February

February 28, 2014

NCI to Implement More Transparent Formula For Calculating Cancer Center Support Grants

June 11, 2014

In Brief: Cancer Series Helps Do In Woodward As Post Metro Editor; OCC RFP Canceled, to Reappear As 4-5 RFPs

January 15, 1982